{"id":"W3146762921","doi":"10.1016/j.jtct.2021.03.029","title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report","year":2021,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Manitoba; British Columbia Children's Hospital; CancerCare Manitoba","funders":"Pharmacyclics; Universität Hamburg; Meiji Seika Pharma; Compass Therapeutics; Syndax Pharmaceuticals; CTI Biopharma; Alvin J. Siteman Cancer Center; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Omeros Corporation; Anthony Nolan; Huntsman Cancer Institute; Takeda Pharmaceuticals U.S.A.; Massachusetts General Hospital; University of Minnesota; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; University at Buffalo; AbbVie; Clinical Science Research and Development; Universidad de Sevilla; National Cancer Institute; Gilead Sciences; Dana-Farber Cancer Institute; Roche; Novartis; Celgene; Bristol-Myers Squibb; AstraZeneca; CareDx; Incyte; Pfizer; Amgen; U.S. Department of Veterans Affairs","keywords":"Medicine; Graft-versus-host disease; Intensive care medicine; Clinical trial; Disease; Hematopoietic stem cell transplantation; Hematopoietic cell; Psychological intervention; Transplantation; Malignancy; Immunology; Internal medicine; Haematopoiesis; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.3262555,0.002892538,0.009179132,0.006996596,0.005392725,0.01308633,0.01561437,0.02436964,0.009854708],"category_scores_gemma":[0.3879412,0.003925362,0.01133918,0.01035417,0.006335676,0.005251897,0.01284425,0.02560386,0.009972665],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01076799,"about_ca_system_score_gemma":0.06906542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0117011,"about_ca_topic_score_gemma":0.0213087,"domain_scores_codex":[0.7306089,0.161581,0.05875463,0.004253203,0.03905682,0.005745559],"domain_scores_gemma":[0.4906943,0.287055,0.05427576,0.02049698,0.1250504,0.0224277],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002162216,0.0004456931,0.004118008,0.02288695,0.0010258,0.0003330347,0.0009610003,0.001373368,0.001109983,0.02203826,0.7823686,0.161177],"study_design_scores_gemma":[0.006088562,0.000636948,0.01522091,0.06746575,0.002556179,0.0008983444,0.001090832,0.0023927,0.002739268,0.0363933,0.8640444,0.0004728167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.005302708,0.1239106,0.1360311,0.3502299,0.0519489,0.1875114,0.03619866,0.003090103,0.1057767],"genre_scores_gemma":[0.01799674,0.03013556,0.6059381,0.1216238,0.006563922,0.1705035,0.02608835,0.001187015,0.01996302],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.3262555,"threshold_uncertainty_score":0.830847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2873942891593231,"score_gpt":0.4623925765223438,"score_spread":0.1749982873630206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}